A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide,and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas

Trial Profile

A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide,and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Etoposide (Primary) ; Oxaliplatin (Primary) ; Ifosfamide
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms OXALET
  • Most Recent Events

    • 25 Jul 2012 Lead trial investigator changed from Lisa M. McGregor to Alberto Pappo as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Planned end date changed from 1 Jun 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top